Research collaboration to develop optimized affinity CD38 CAR-NK and DR5 TRAILv in Multiple Myeloma (MM) with Dr Tuna Mutis, Professor Immunotherapy of Haematological Malignancies, Department of Hematology at Amsterdam University Medical Center (UMC), Amsterdam, Netherlands.
Collaboration to investigate bortezomib and DR5 TRAIL variant expressing NK cells in cancer models with Dr Richard Childs, Clinical Director NHLBI at the National Institutes of Health (NIH), Bethesda, MD, USA. Dr Childs is a pioneer of cellular immunotherapy.
Research agreement with Dr Eva Szegezdi, Lecturer in Biochemistry, NUI Galway, Galway, Ireland and Head of the Blood Cancer Biobank in Ireland, to explore the optimal application of CLL-1 targeting strategies in pre-clinical models of Acute Myeloid Leukaemia (AML). Dr Szegezdi is an expert in apoptosis and the (AML) microenvironment.
Research collaboration with Dr David Finlay, Associate Professor, Immunometabolism, Biochemistry, Trinity Research at Trinity College, Dublin, Ireland to explore novel approaches to enhance NK cell metabolism. Dr Finlay is a world authority on NK cell metabolism. Studies are funded through an Enterprise Ireland, Innovation Partnership grant.
The Centre for Cell Manufacturing Ireland at NUI Galway, Ireland is one of the country’s first state-of-the-art licensed GMP facility. ONK has access to 250 m2 cleanroom facility to enable ongoing R&D in NK cell manufacturing.
Robust partnership spanning process development and optimization of manufacturing through to scaled-up GMP manufacturing for initial clinical trials.
License from the National Institutes of Health (NIH), Bethesda, MD, USA for the rights to make and use a clinically-validated GMP grade EBV-LCL feeder cell line. This will enable robust NK cell expansion, supporting scale-up of the company’s manufacturing process to enable clinical trials.
Option license for the CCR7 homing receptor, for exploration in our ONKT101 program for relapsed/ refractory B cell malignancies.
Option license from Glycotope GmbH for humanized scFv targeting a novel tumor-specific MUC1 glycopeptide epitope, to support our ONKT103 program for solid tumors.
Option license from Cellerant Therapeutics for humanized scFv targeting CLL-1 to support our ONKT104 program for the treatment of AML.
Exclusive global license from Walter and Elizabeth Hall Institute (WEHI) to its patent for CISH knock out in NK cells for the treatment of cancer.
Our ONKT101 program, a dual-targeted NK cell therapy incorporating a CD19 CAR and TRAILv targeting the death receptor pathway (DR5) intended for the treatment of relapsed/refractory B cell malignancies, is partnered with Avectas and will utilize their proprietary SOLUPORE® technology as a means of non-viral genetic modification.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Google Analytics Cookies
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them: